Beijing Aosaikang Pharmaceutical (SHE:002755), through a unit, said the drug ASKB589 showed positive results in a phase Ib/II clinical trial, according to a Shenzhen bourse filing on Tuesday.
The drug ASKB589, in combination with CAPOX and a PD-1 inhibitor, was tested as first-line treatment of advanced gastric cancer.
The Chinese pharmaceutical company's unit, AskGene, told attendees at the European Society for Medical Oncology in Germany the trial confirmed the drug's durable antitumor activity and overall survival benefit in patients.
Aosaikang's shares slipped less than 2% during midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments